Skip To Main Content
Cara Smith on Muck Rack

Cara Smith

Verified
Washington, D.C.
As seen in: Inside Health Policy, Environmental Health Perspectives, MSN, Yahoo Entertainment, Yahoo Life, Nature, Wiley Online Library, Yahoo News, PLOS ONE, Yahoo Finance, MarketWatch and
made in nj | she/her | health tech managing editor @inhealthpolicy | opinions my own | formerly: @qctimes, @dispatch_argus
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Cara

Contact Cara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Court Order Directs FDA To Justify Mifepristone REMS Requirements

|
By Cara Smith Verified, Jessica Karins Verified
| Inside Health Policy Verified
FDA’s regulation of mifepristone is facing another layer of uncertainty with a Virginia federal court handing down a decision Thursday (July 23) mandating the agency review its existing restrictions on prescription of the abortion drug, finding them arbitrary and capricious under the Administrative Procedure Act (APA).
Open in Who Shared Issue with article?

Cassidy's Health Privacy Bill Again Scheduled For Committee Markup

|
By Cara Smith Verified
| Inside Health Policy Verified
Senate health committee Chair Bill Cassidy's (R-LA) health privacy legislation is now slated to be marked up on Thursday (July 30) following the committee's quiet removal of the legislation from a markup earlier this week.
Open in Who Shared Issue with article?

PCAC's Peptide Recommendations Could Offer Boon For Telehealth Companies

|
By Cara Smith Verified
| Inside Health Policy Verified
Mainstream telehealth platforms like Hims & Hers could see a huge market boost if FDA goes along with its compounding advisors’ calls to add popular “wellness” peptides to the 503A Bulks List, which would allow state-regulated compounding facilities to legitimately sell the products that are currently flooding the unregulated “grey market.”
Open in Who Shared Issue with article?
See all 6,335 licensed articles (6,777 Total)